- Conditions: Advanced Neoplasm; MicroRNA-21 (miR-21) and miR-92
Intervention:
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Pain
Intervention: Device: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong; The Hong Kong Polytechnic University
Completed - verified March 2012 - Condition: Aggression
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Multi-vitamin/mineral; Dietary Supplement: Docosahexaenoic acid; Dietary Supplement: DHA plus vitamins/minerals
Sponsors: Swansea University; Swansea University
Completed - verified March 2012 - Condition: Asthma
Interventions: Drug: SERETIDE Rotacaps; Drug: SERETIDE Diskus
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Biliary Stricture
Interventions: Device: WallFlex™ Biliary RX Fully Covered Stent System RMV; Device: Commercially available Plastic Stent Per Investigator preference
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Not yet recruiting - verified February 2012 - Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg, fasted state); Drug: Dutasteride (0.5mg, fed state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state); Drug: Harnal-D Tablets with water (fasted state); Drug: Harnal-D Tablets with water (fed state); Drug: Harnal-D tablets without water (fasted state)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Asthma
Interventions: Biological: SB-240563; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012 - Condition: Acute Bronchiolitis
Intervention: Device: 3% hypertonic saline
Sponsors: Sheffield Children's NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; University of Sheffield
Recruiting - verified October 2011 - Conditions: Smoking; Non-smoking
Intervention: Other: Part A
Sponsors: Philip Morris Products S.A.; Philip Morris Products S.A.
Completed - verified December 2011 - Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg); Drug: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg); Drug: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011 - Condition: Intrinsic Aging of Skin
Intervention: Device: Tropoelastin
Sponsors: Elastagen Pty Ltd; Elastagen Pty Ltd
Recruiting - verified February 2012 - Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Condition: Infections, Pseudomonas
Interventions: Drug: Colistimethate sodium; Drug: Saline
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK2018682; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Colonic Adenomas
Intervention: Device: Bright Narrow Band Imaging
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: A; Drug: B; Drug: C; Drug: D; Drug: E; Drug: F
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Menstrual Problem
Intervention: Drug: Marvelon
Sponsors: Family Planning Association New South Wales; Family Planning Association New South Wales; Merck
Not yet recruiting - verified June 2011 - Condition: Adenomatous Polyp of Large Intestine
Intervention: Procedure: Prophylactic use of coagulation therapy
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Pain
Interventions: Procedure: Electroacupuncture; Procedure: Sham acupuncture
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Not yet recruiting - verified June 2011 - Condition: Multiple Sclerosis
Interventions: Drug: GSK2018682; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: A; Drug: B; Drug: C; Drug: D
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Condition: Cognition
Intervention: Procedure: Transcranial direct current stimulation (tDCS)
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified September 2010 - Condition: Effects on Learning
Intervention: Device: Transcranial direct current stimulation (tDCS)
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2011 - Conditions: Obesity; Overweight
Interventions: Device: Active, implantable, intra abdominal vagal blocking medical device (Maestro RC2 System); Device: Active, implantable, intra abdominal vagal blocking medical device (Maestro RC2 System)
Sponsors: EnteroMedics; EnteroMedics
Active, not recruiting - verified April 2012 - Condition: Skin Conditions
Interventions: Device: ELAPR; Device: ELAPR
Sponsors: Elastagen Pty Ltd; Elastagen Pty Ltd
Completed - verified November 2011 - Condition: Influenza Infection
Intervention: Biological: GSK Biologicals' investigational vaccine GSK1562902A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.; Monash University
Recruiting - verified February 2012 - Condition: Gastroparesis
Interventions: Drug: GSK1322888; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Prostatic Hyperplasia
Intervention: Drug: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Prophylaxis of Ross River Virus Infection
Intervention: Biological: Ross River Virus Vaccine
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Active, not recruiting - verified October 2011 - Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder); HMSN
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute of Neurological Disorders and Stroke (NINDS); Muscular Dystrophy Association; University of Rochester; University of Pennsylvania; National Hospital for Neurology and Neurosurgery; The Childrens Hospital of Westmead; Children's Hospital of Philadelphia; University of Miami; Johns Hopkins University; University of Washington
Recruiting - verified October 2011 - Condition: Charcot Marie Tooth Disease
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute of Neurological Disorders and Stroke (NINDS); Muscular Dystrophy Association; National Hospital of Neurology and Neurosurgery, Queens Square, London, UK; The Children's Hospital at Westmead; University of Rochester; University of Miami; University of Pennsylvania; Childrens Hospital of Philadelphia; C. Besta Neurological Institute; Johns Hopkins University; University of Washington
Recruiting - verified October 2011 - Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Device: Marketed nasal strip; Device: NexGen AB 2R11; Device: NexGen JB Organic PET/PE
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Nasopharyngeal Cancer; Epstein-Barr Virus Infections
Intervention: Biological: MVA-EBNA1/LMP2 Inj. vaccine
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011 - Condition: Cognitive Dysfunction
Intervention: Other: Cognitive assessment
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified December 2009 - Condition: Infections
Interventions: Drug: echinacea; Drug: placebo
Sponsors: Bioforce AG; Bioforce AG
Completed - verified June 2011 - Condition: Meningococcal Disease
Intervention: Biological: MenACWY conjugate vaccine plus routine infant vaccines
Sponsors: Novartis; Novartis Vaccines
Completed - verified March 2012 - Condition: Chronic Kidney Disease
Interventions: Other: Progressive resistance training programme; Other: Sham exercise; Other: Progressive resistance training; Other: Sham exercise
Sponsors: Bangor University; Bangor University; Betsi Cadwaladr University Health Board
Completed - verified December 2011 - Condition: Hypercholesterolemia
Interventions: Dietary Supplement: Wheat bran; Dietary Supplement: 3g high MW; Dietary Supplement: 4g medium MW; Dietary Supplement: 3g medium MW; Dietary Supplement: 4g low MW
Sponsors: Glycemic Index Laboratories, Inc; Glycemic Index Laboratories, Inc; CreaNutrition, AG; University of Guelph; University of Sydney; Laval University; Reading Scientific Services, Ltd.; University of Toronto; Agriculture and Agri-Food Canada
Completed - verified June 2011 - Condition: Contraception
Intervention: Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Sponsors: Bayer; Bayer
Completed - verified October 2011 - Condition: Contraception
Intervention: Drug: Levonorgestrel IUS (LCS, BAY86-5028)
Sponsors: Bayer; Bayer
Active, not recruiting - verified March 2012 - Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011 - Condition: Attention Deficit/Hyperactivity Disorder
Interventions: Drug: Short Acting Methylphenidate; Drug: Long Acting Methylphenidate
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified January 2012 - Condition: Neurofibromatosis Type 1
Interventions: Drug: Lovastatin ™; Device: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine; The Children's Hospital at Westmead
Recruiting - verified July 2011 - Condition: Influenza
Interventions: Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011 - Conditions: Coronary Heart Disease; Acute Coronary Syndrome; Impaired Glucose Tolerance; Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: Acarbose; Drug: Matching Placebo
Sponsors: University of Oxford; University of Oxford; Bayer
Recruiting - verified September 2011 - Condition: Osteonecrosis
Interventions: Drug: Zoledronic Acid; Drug: Placebo
Sponsors: University of Sydney; University of Sydney; Novartis
Recruiting - verified February 2011 - Conditions: Alzheimer Disease; Amyloid Beta-Protein
Intervention: Drug: Florbetaben (BAY94-9172)
Sponsors: Bayer; Bayer
Completed - verified December 2011 - Condition: Hepatitis B
Intervention: Other: Incentive condition
Sponsors: Kirby Institute; Kirby Institute
Completed - verified June 2011 - Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram; Drug: Sertraline; Drug: Venlafaxine XR
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified March 2012 - Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012 - Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012 - Conditions: Healthy Subjects; Asthma
Intervention: Drug: GW642444M, GW685698X
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Conditions: Chronic Diseases Associated With Axonal Damage; Cerebrovascular Accident
Interventions: Drug: GSK249320; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2011 - Condition: Influenza
Interventions: Biological: CSL Limited Influenza Vaccine; Biological: Placebo
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: molecular diagnostic method; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); National Cancer Research Network
Recruiting - verified September 2007 - Condition: Influenza
Intervention: Biological: Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Completed - verified September 2011 - Conditions: Healthy Subjects; Anaemia
Interventions: Drug: GSK626616, placebo, midazolam; Drug: omeprazole, caffeine, flurbiprofen, rosiglitazone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Asthma
Interventions: Drug: GSK679586; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Hepatic Impairment; Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: eltrombopag
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: Meningococcal Infection; Haemophilus Infection
Interventions: Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine); Biological: Priorix™; Biological: Hiberix™; Biological: Meningitec™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011 - Condition: Glaucoma
Intervention:
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Eye Hospital; Prince of Wales Hospital, Shatin, Hong Kong
Recruiting - verified June 2011 - Condition: Herpes Simplex
Interventions: Biological: GSK208141; Biological: HavrixTM (investigational formulation); Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: HIV Infections; Dyslipidemias; Glucose Metabolism Disorders; Metabolic Diseases; Lipodystrophy; Cardiovascular Disease
Interventions: Drug: Combivir (zidovudine [AZT] / lamivudine [3TC]); Drug: Kaletra (lopinavir [LPVr])
Sponsors: Kirby Institute; Kirby Institute; St Vincent's Hospital, Sydney; National Heart, Lung, and Blood Institute (NHLBI); Garvan Institute of Medical Research; Prince of Wales Hospital, Sydney
Completed - verified April 2012 - Conditions: Hepatitis B; Hepatitis A
Intervention: Biological: Combined Hepatitis A and B vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011 - Condition: Prophylaxis Hepatitis B
Interventions: Biological: Engerix™-B (thiomersal-free) 20µg; Biological: 10 μg Engerix™-B (preservative-free); Biological: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Conditions: HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease
Interventions: Drug: Lamivudine; Drug: Stavudine; Drug: Didanosine; Drug: Zidovudine; Drug: Tenofovir; Drug: Abacavir; Drug: Efavirenz (EFV); Drug: Nevirapine; Drug: Indinavir; Drug: Saquinavir; Drug: Amprenavir; Drug: Ritonavir; Drug: Nelfinavir; Drug: Tipranavir; Drug: enfuvirtide (T20)
Sponsors: Kirby Institute; Kirby Institute; St Vincent's Hospital, Sydney; National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2012 - Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsors: Queen Mary University of London; Jill Knox
Active, not recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
 |
Join Clinical Trials for Healthy Volunteers in Wales |
